prikaz prve stranice dokumenta Prognostic significance of survivin and Caspase-3 immunohistochemical expression in patients with diffuse large B-cell lymphoma treated with rituximab and CHOP
  Download
PDF 247.77 KB
Scientific paper - Original scientific paper
Prognostic significance of survivin and Caspase-3 immunohistochemical expression in patients with diffuse large B-cell lymphoma treated with rituximab and CHOP
Pathology Oncology Research, 17 (2011), 2; 243-247. https://doi.org/10.1007/s12253-010-9304-4
Mitrović, Zdravko; Ilić, Ivana; Aurer, Igor; Bašić-Kinda, Sandra; Radman, Ivo; Dotlić, Snježana; Ajduković, Radmila; Labar, Boris

Institutional repository: Dr Med - University of Zagreb School of Medicine Digital Repository

Cite this document

Mitrović, Z., Ilić, I., Aurer, I., Bašić Kinda, S., Radman, I., Dotlić, S. ... Labar, B. (2011). Prognostic significance of survivin and Caspase-3 immunohistochemical expression in patients with diffuse large B-cell lymphoma treated with rituximab and CHOP. Pathology Oncology Research, 17. (2), 243-247. doi: 10.1007/s12253-010-9304-4

Mitrović, Zdravko, et al. "Prognostic significance of survivin and Caspase-3 immunohistochemical expression in patients with diffuse large B-cell lymphoma treated with rituximab and CHOP." Pathology Oncology Research, vol. 17, no. 2, 2011, pp. 243-247. https://doi.org/10.1007/s12253-010-9304-4

Mitrović, Zdravko, Ivana Ilić, Igor Aurer, Sandra Bašić Kinda, Ivo Radman, Snježana Dotlić, Radmila Ajduković and Boris Labar. "Prognostic significance of survivin and Caspase-3 immunohistochemical expression in patients with diffuse large B-cell lymphoma treated with rituximab and CHOP." Pathology Oncology Research 17, no. 2 (2011): 243-247. https://doi.org/10.1007/s12253-010-9304-4

Mitrović, Z., et al. (2011) 'Prognostic significance of survivin and Caspase-3 immunohistochemical expression in patients with diffuse large B-cell lymphoma treated with rituximab and CHOP', Pathology Oncology Research, 17(2), pp. 243-247. doi: 10.1007/s12253-010-9304-4

Mitrović Z, Ilić I, Aurer I, Bašić Kinda S, Radman I, Dotlić S, and sur.. Prognostic significance of survivin and Caspase-3 immunohistochemical expression in patients with diffuse large B-cell lymphoma treated with rituximab and CHOP. Pathology Oncology Research [Internet]. 2011 June [cited 2024 November 26];17(2):243-247. doi: 10.1007/s12253-010-9304-4

Z. Mitrović, et al., "Prognostic significance of survivin and Caspase-3 immunohistochemical expression in patients with diffuse large B-cell lymphoma treated with rituximab and CHOP", Pathology Oncology Research, vol. 17, no. 2, pp. 243-247, June 2011. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:105:221136. [Accessed: 26 November 2024]

Metadata
Title (english)Prognostic significance of survivin and Caspase-3 immunohistochemical expression in patients with diffuse large B-cell lymphoma treated with rituximab and CHOP
AuthorZdravko Mitrović
AuthorIvana Ilić
AuthorIgor Aurer
AuthorSandra Bašić-Kinda
AuthorIvo Radman
AuthorSnježana Dotlić
AuthorRadmila Ajduković
AuthorBoris Labar
Author's institutionUniversity of Zagreb
School of Medicine
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Clinical Medical Sciences
Abstract (english)
Survivin is an inhibitor of apoptosis whose expression may be associated with inferior outcome in patients with diffuse large B-cell lymphoma (DLBCL) treated without rituximab. Caspase-3 is the final caspase of the apoptotic cascade and its pattern of expression may also be related to patients' outcome. In this study we investigated immunohistochemical expression of survivin and caspase-3 (CPP32) in 57 patients with DLBCL treated with rituximab and CHOP (R-CHOP). According to previously published criteria, we separately analyzed correlation of different types of survivin expression with patients' outcome. Nuclear survivin was expressed in only 26% of cases, cytoplasmic survivin was expressed in 81% of cases while application of immunoreactivity scoring system yielded 58% of survivin positive cases. Caspase-3 was expressed in 77% of cases. There were no significant correlations between any type of survivin expression and response to treatment or survival of the patients. The expression of caspase-3 was also not associated with patients' outcome. We conclude that survivin and caspase-3 have no significant prognostic significance in patients with DLBCL treated with R-CHOP.
Keywords (english)
Languageenglish
Publication typeScientific paper - Original scientific paper
Publication statusPublished
Peer reviewPeer review
Publication versionAccepted version
Journal titlePathology Oncology Research
Numberingvol. 17, no. 2, pp. 243-247
p-ISSN1219-4956
DOIhttps://doi.org/10.1007/s12253-010-9304-4
URN:NBNurn:nbn:hr:105:221136
Publication2011-06
Document URLhttps://doi.org/10.1007/s12253-010-9304-4
Type of resourceText
Access conditionsOpen access
Terms of useLicence In copyright icon
Created on2024-03-28 11:49:02